Mannucci P M, Schimpf K, Abe T, Aledort L M, Anderle K, Brettler D B, Hilgartner M W, Kernoff P B, Kunschak M, McMillan C W
Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Milan, Italy.
Transfusion. 1992 Feb;32(2):134-8. doi: 10.1046/j.1537-2995.1992.32292180141.x.
A multicenter prospective study was carried out to evaluate whether a vapor-heated factor VIII concentrate transmitted blood-borne viral infections over a surveillance period of 15 months. Thirty-five patients with hemophilia and von Willebrand disease who had never received any blood components were treated. Twenty-eight were analyzed and found not to have non-A, non-B hepatitis. Sera from 20 of these 28 patients were also tested for the antibody to the hepatitis C virus. None had sero-converted during the follow-up period. None of the patients analyzed developed markers of the hepatitis B virus (n = 17) or the human immunodeficiency virus (n = 31). This vapor-heated factor VIII concentrate carries a low risk of transmitting hepatitis and human immunodeficiency virus infection.
开展了一项多中心前瞻性研究，以评估一种蒸汽加热的凝血因子VIII浓缩剂在15个月的监测期内是否传播血源性病毒感染。对35例从未接受过任何血液成分的血友病和血管性血友病患者进行了治疗。对其中28例进行分析，发现没有非甲非乙型肝炎。还对这28例患者中的20例血清进行了丙型肝炎病毒抗体检测。在随访期间，无人血清学转换。所分析的患者中，无人出现乙型肝炎病毒标志物（n = 17）或人类免疫缺陷病毒标志物（n = 31）。这种蒸汽加热的凝血因子VIII浓缩剂传播肝炎和人类免疫缺陷病毒感染的风险较低。
